Abcam Licenses Novel Ceefourin Inhibitors of Multidrug Resistance Protein 4 from Children’s Cancer Institute
September 19, 2014
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development
Sydney, Australia and Cambridge, UK, 19 September, 2014: Children’s Cancer Institute and Abcam plc, a global leader in the supply of innovative protein research tools and services, announced today that they have entered into an exclusive licence, supply and distribution agreement for multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ 2, for research purposes.
The first known selective inhibitors of MRP4, Ceefourin™ 1 and Ceefourin™ 2 are potent, chemically distinct compounds and are the first known selective inhibitors of MRP4, and represent important tools for investigating essential cellular processes such as multidrug resistance. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
MRP4 is a protein that belongs to the ATP-Binding Cassette (ABC) transporter superfamily of membrane pumps that export molecules from the cell. MRP4 effectively effluxes elements that are potentially toxic to the cell, protecting it from deleterious chemical build ups and from xenobiotics, such as environmental toxins.
Previous research on MRP4 and other ABC transporter family members has shown that these proteins are often ‘hijacked’ by cancer cells, which produce them at high levels to pump out chemotherapy drugs, effectively protecting the cancer cells from treatment.
The novel MRP4 inhibitors, Ceefourin™ 1 and Ceefourin™ 2, discovered and characterised by Children’s Cancer Institute, are exciting new tools for researchers, allowing the further exploration of MRP4 function and potentially the basis for developing therapeutic drugs to treat cancer.
Lead researcher and Children’s Cancer Institute Deputy Director, Professor Murray Norris, said “High-throughput screening has identified Ceefourin™ 1 and Ceefourin™ 2 as highly selective inhibitors of MRP4. Up to this point, researchers have not had access to effective MRP4 inhibitors without substantial confounding off-target effects – so this is quite an advancement for the field. Highly specific research reagents are of course crucial to accurately defining how these proteins work.
“We are delighted to now be able to make these research reagents available to the scientific community worldwide through our partnership with Abcam. These compounds should enable researchers to obtain new insights into MRP4 function and to modulate extracellular drug transport.”
Matthew Roe, Head of Reagents, Abcam said: “We are very pleased to partner with Children’s Cancer Institute, and to manage distribution of these reagents to the research community, helping to increase the impact of their findings and help scientists discover more.”
The Ceefourin MRP4 inhibitors now available from Abcam include:
Ceefourin™ 1 (ab145144)
Selective MRP4 inhibitor. Benzothiazol compound which potently and selectively inhibits MRP4-mediated substrate efflux. For example, Ceefourin 1 inhibits MRP4-mediated D-luciferin transport (IC50 = 1.5µM) as measured indirectly using a bioluminescence assay in HEK293-MRP4 cells with stable luciferase expression. Ceefourin 1 exhibits no detectable inhibition of other ABC transporters such as Pgp, ABCG2 and MRP1, MRP2, MRP3 and MRP5, and is non-toxic in normal fibroblast and cancer cell lines tested up to 50µM. Ceefourin 1 displays metabolic (>30 min) and acid stability (>24hrs at 37oC, pH 2) in a mouse liver microsomal assay and acid-stability assay, respectively.
Ceefourin™ 2 (ab145145)
Selective MRP4 inhibitor. Pyrazolopyrimidine compound which potently inhibits MRP4-mediated substrate efflux. For example, Ceefourin 2 inhibits MRP4-mediated D-luciferin transport (IC50 = 7.0µM) as measured indirectly using a bioluminescence assay in HEK293-MRP4 cells with stable luciferase expression. Ceefourin 2 exhibits no detectable inhibition of other ABC transporters, such as Pgp, ABCG2 and MRP1, MRP2, MRP3 and MRP5. Ceefourin 2 displayed limited toxicity in two of eleven cancer cell lines tested up to 50µM, and exhibited no toxicity in two normal fibroblast lines tested to the same concentration. Ceefourin 2 shows metabolic stability (>30 min) in a mouse liver microsomal assay and limited acid-stability (half life < 2 hr at 37oC, pH 2).
Ceefourin™ is a trademark of Children’s Cancer Institute. Ceefourin 1 and Ceefourin 2 are claimed under Australian provisional patent application 2014902472.
Reference: High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Published in Biochemical Pharmacology.
Tel: +44 (0)7787 502 947
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision is to save the lives of all children with cancer and improve their long-term health, through research. The Institute has grown to now employ nearly 300 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.